The giant global potential for an Alzheimer’s drug and the fear of missing out lured Biogen and Wall Street to make the same bet others have lost. rob_cyran
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a.
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request aIndonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Baca lebih lajut »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open.
Baca lebih lajut »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Baca lebih lajut »
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Baca lebih lajut »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Baca lebih lajut »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
Baca lebih lajut »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Baca lebih lajut »
Stocks inch higher, led by AppleStocks fell at the open after the Fed’s latest policy announcement sparked worries about the U.S. economy while shares of Biogen dragged down the health care sector.
Baca lebih lajut »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Baca lebih lajut »